Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa.

Boyd A, Kouamé MG, Houghtaling L, Moh R, Gabillard D, Maylin S, Abdou Chekaraou M, Delaugerre C, Anglaret X, Eholié SP, Danel C, Zoulim F, Lacombe K; ANRS 12136 Temprano and ANRS 12240 VarBVA studies.

Trans R Soc Trop Med Hyg. 2019 Aug 1;113(8):437-445. doi: 10.1093/trstmh/trz021.

PMID:
31574151
2.

FHL1 is a major host factor for chikungunya virus infection.

Meertens L, Hafirassou ML, Couderc T, Bonnet-Madin L, Kril V, Kümmerer BM, Labeau A, Brugier A, Simon-Loriere E, Burlaud-Gaillard J, Doyen C, Pezzi L, Goupil T, Rafasse S, Vidalain PO, Bertrand-Legout A, Gueneau L, Juntas-Morales R, Ben Yaou R, Bonne G, de Lamballerie X, Benkirane M, Roingeard P, Delaugerre C, Lecuit M, Amara A.

Nature. 2019 Oct;574(7777):259-263. doi: 10.1038/s41586-019-1578-4. Epub 2019 Sep 25.

PMID:
31554973
3.

Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis.

Gras J, Mahjoub N, Charreau I, Cotte L, Tremblay C, Chas J, Raffi F, Cua E, Guillon B, Guigue N, Chaix ML, Meyer L, Molina JM, Delaugerre C; and the Ipergay study group.

AIDS. 2019 Sep 2. doi: 10.1097/QAD.0000000000002364. [Epub ahead of print]

PMID:
31483372
4.

Proliferative memory SAMHD1low CD4+ T cells harbour high levels of HIV-1 with compartmentalized viral populations.

Hani L, Chaillon A, Nere ML, Ruffin N, Alameddine J, Salmona M, Lopez Zaragoza JL, Smith DM, Schwartz O, Lelièvre JD, Delaugerre C, Lévy Y, Seddiki N.

PLoS Pathog. 2019 Jun 20;15(6):e1007868. doi: 10.1371/journal.ppat.1007868. eCollection 2019 Jun.

5.

Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men.

Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, L'Yavanc T, Ohayon M, Israel G, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E.

Int J Antimicrob Agents. 2019 Oct;54(4):513-517. doi: 10.1016/j.ijantimicag.2019.06.001. Epub 2019 Jun 11.

PMID:
31195120
6.

Shared HCV Transmission Networks Among HIV-1-Positive and HIV-1-Negative Men Having Sex With Men by Ultradeep Sequencing.

Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, Lʼyavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):105-110. doi: 10.1097/QAI.0000000000002099.

PMID:
31169768
7.

A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.

Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V.

J Viral Hepat. 2019 Jul;26(7):846-855. doi: 10.1111/jvh.13101. Epub 2019 May 14.

PMID:
30974483
8.

In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec.

Chaillon A, Delaugerre C, Brenner B, Armero A, Capitant C, Nere ML, Leturque N, Pialoux G, Cua E, Tremblay C, Smith DM, Goujard C, Meyer L, Molina JM, Chaix ML.

Open Forum Infect Dis. 2019 Feb 15;6(3):ofz080. doi: 10.1093/ofid/ofz080. eCollection 2019 Mar.

9.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P; ANRS AC43 Resistance Group.

J Antimicrob Chemother. 2019 May 1;74(5):1368-1375. doi: 10.1093/jac/dkz021.

PMID:
30789205
10.

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.

Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C.

J Antimicrob Chemother. 2019 May 1;74(5):1389-1394. doi: 10.1093/jac/dkz004.

PMID:
30690509
11.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group.

HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

PMID:
30688008
12.

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial.

Chaix ML, Charreau I, Pintado C, Delaugerre C, Mahjoub N, Cotte L, Capitant C, Raffi F, Cua E, Pialoux G, Tremblay C, Meyer L, Molina JM; ANRS IPERGAY Study Group .

Open Forum Infect Dis. 2018 Nov 8;5(11):ofy295. doi: 10.1093/ofid/ofy295. eCollection 2018 Nov.

13.

HIV rapid screening tests and self-tests: Be aware of differences in performance and cautious of vendors.

Mourez T, Lemée V, Delbos V, Delaugerre C, Alessandri-Gradt E, Etienne M, Simon F, Chaix ML, Plantier JC.

EBioMedicine. 2018 Nov;37:382-391. doi: 10.1016/j.ebiom.2018.10.012. Epub 2018 Oct 24.

14.

Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.

Palich R, Ghosn J, Chaillon A, Boilet V, Nere ML, Chaix ML, Delobel P, Molina JM, Lucht F, Bouchaud O, Rieux V, Thiebaut R, Levy Y, Delaugerre C, Lelievre JD; VRI02/ANRS149 LIGHT Vaccine Trial Group.

AIDS. 2019 Feb 1;33(2):279-284. doi: 10.1097/QAD.0000000000002058.

PMID:
30325777
15.

Reconstitution of HIV-1 reservoir following high-dose chemotherapy/autologous stem cell transplantation for lymphoma.

Delagreverie HM, Gerard L, Chaillon A, Roelens M, Djerroudi L, Salmona M, Larghero J, Galicier L, Simon F, Oksenhendler E, Moins-Teisserenc H, Delaugerre C.

AIDS. 2019 Feb 1;33(2):247-257. doi: 10.1097/QAD.0000000000002051.

PMID:
30325771
16.

CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.

Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, Launay O, Lacombe JM, Menard A, De Truchis P, Delfraissy JF, Weiss L, Costagliola D; FHDH-ANRS CO4.

AIDS. 2018 Nov 13;32(17):2605-2614. doi: 10.1097/QAD.0000000000002010.

PMID:
30289817
17.

Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Danel C, Delaugerre C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

Liver Int. 2019 Feb;39(2):280-289. doi: 10.1111/liv.13975. Epub 2018 Oct 17.

18.

Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.

Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM.

AIDS. 2018 Sep 24;32(15):2161-2169. doi: 10.1097/QAD.0000000000001939.

PMID:
30212403
19.

Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.

Rodriguez C, Nere ML, Demontant V, Charreau I, Mercier-Darty M, Delagreverie H, Salmona M, de Castro N, Chaix ML, Molina JM, Delaugerre C.

J Antimicrob Chemother. 2018 Nov 1;73(11):3122-3128. doi: 10.1093/jac/dky315.

PMID:
30137335
20.

Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing.

Raymond S, Delaugerre C, Nicot F, Assoumou L, Lancar R, Beniguel L, Izopet J; ANRS 146 OPTIMAL study group.

AIDS. 2018 Oct 23;32(16):2429-2431. doi: 10.1097/QAD.0000000000001976.

PMID:
30102658
21.

Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial.

Delaugerre C, Rodriguez C, Capitant C, Nere ML, Mercier-Darty M, Carette D, Pialoux G, Cotte L, Charreau I, Molina JM; IPERGAY study group.

AIDS. 2018 Oct 23;32(16):2353-2361. doi: 10.1097/QAD.0000000000001960.

PMID:
30096070
22.

HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line.

Fily F, Ayikobua E, Ssemwanga D, Nicholas S, Kaleebu P, Delaugerre C, Pasquier E, Amoros Quiles I, Balkan S, Schramm B.

Trop Med Int Health. 2018 Oct;23(10):1075-1083. doi: 10.1111/tmi.13131.

23.

TIM-1 Ubiquitination Mediates Dengue Virus Entry.

Dejarnac O, Hafirassou ML, Chazal M, Versapuech M, Gaillard J, Perera-Lecoin M, Umana-Diaz C, Bonnet-Madin L, Carnec X, Tinevez JY, Delaugerre C, Schwartz O, Roingeard P, Jouvenet N, Berlioz-Torrent C, Meertens L, Amara A.

Cell Rep. 2018 May 8;23(6):1779-1793. doi: 10.1016/j.celrep.2018.04.013.

24.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).

Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L; ANRS AC-11 Resistance Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2147-2151. doi: 10.1093/jac/dky142.

PMID:
29718247
25.

Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Delaugerre C, Danel C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

J Viral Hepat. 2018 Oct;25(10):1121-1131. doi: 10.1111/jvh.12914. Epub 2018 May 9.

PMID:
29660214
26.

Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection.

Stefic K, Novelli S, Mahjoub N, Seng R, Molina JM, Cheneau C, Barin F, Chaix ML, Meyer L, Delaugerre C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) PRIMO Study Group.

J Infect Dis. 2018 May 5;217(11):1793-1797. doi: 10.1093/infdis/jiy120.

PMID:
29509924
27.

A Global Interactome Map of the Dengue Virus NS1 Identifies Virus Restriction and Dependency Host Factors.

Hafirassou ML, Meertens L, Umaña-Diaz C, Labeau A, Dejarnac O, Bonnet-Madin L, Kümmerer BM, Delaugerre C, Roingeard P, Vidalain PO, Amara A.

Cell Rep. 2018 Jan 30;22(5):1364. doi: 10.1016/j.celrep.2018.01.038. No abstract available.

28.

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.

Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D.

J Antimicrob Chemother. 2018 Apr 1;73(4):1039-1044. doi: 10.1093/jac/dkx511.

PMID:
29342281
29.

A Global Interactome Map of the Dengue Virus NS1 Identifies Virus Restriction and Dependency Host Factors.

Hafirassou ML, Meertens L, Umaña-Diaz C, Labeau A, Dejarnac O, Bonnet-Madin L, Kümmerer BM, Delaugerre C, Roingeard P, Vidalain PO, Amara A.

Cell Rep. 2017 Dec 26;21(13):3900-3913. doi: 10.1016/j.celrep.2017.11.094. Erratum in: Cell Rep. 2018 Jan 30;22(5):1364.

30.

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8.

PMID:
29229440
31.

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.

PMID:
28747274
32.

Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs.

Delaugerre C, Antoni G, Mahjoub N, Pialoux G, Cua E, Pasquet A, Hall N, Tremblay C, Cotte L, Capitant C, Chaix ML, Meyer L, Molina JM; IPERGAY Study Group.

J Infect Dis. 2017 Aug 1;216(3):382-386. doi: 10.1093/infdis/jix297.

PMID:
28666370
33.

Performance of the Liaison® XL Murex recHTLV-I/II Immunoassay in the Detection of HTLV-1/2 Antibodies in Serum.

Gantner P, Velay A, Guigue N, Barth H, Wendling MJ, Delaugerre C, Fafi-Kremer S.

Clin Lab. 2017 May 1;63(5):997-1001. doi: 10.7754/Clin.Lab.2017.161026.

PMID:
28627820
34.

Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.

Gantner P, Mélard A, Damond F, Delaugerre C, Dina J, Gueudin M, Maillard A, Sauné K, Rodallec A, Tuaillon E, Plantier JC, Rouzioux C, Avettand-Fenoel V; ANRS-AC11 Quantification Working Group.

J Med Virol. 2017 Nov;89(11):2047-2050. doi: 10.1002/jmv.24874. Epub 2017 Jul 6.

PMID:
28617961
35.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2351-2354. doi: 10.1093/jac/dkx128.

PMID:
28472307
36.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.

Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773. doi: 10.1093/jac/dkx042.

PMID:
28333232
37.

Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies.

Chaillon A, Essat A, Frange P, Smith DM, Delaugerre C, Barin F, Ghosn J, Pialoux G, Robineau O, Rouzioux C, Goujard C, Meyer L, Chaix ML; on behalf the ANRS PRIMO Cohort Study.

Retrovirology. 2017 Feb 21;14(1):15. doi: 10.1186/s12977-017-0339-4.

38.

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.

Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM.

J Antimicrob Chemother. 2017 Feb;72(2):478-485. doi: 10.1093/jac/dkw412. Epub 2016 Sep 28.

PMID:
28073964
39.

Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.

Stefic K, Salmona M, Capitao M, Splittgerber M, Maakaroun-Vermesse Z, Néré ML, Bernard L, Chaix ML, Barin F, Delaugerre C.

J Antimicrob Chemother. 2017 Mar 1;72(3):850-854. doi: 10.1093/jac/dkw507.

PMID:
27999055
40.

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents.

Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ.

Open Forum Infect Dis. 2016 Oct 7;3(4):ofw189. eCollection 2016 Oct. Review.

41.

Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?

Pialoux G, Delaugerre C, Cotte L, Raffi F, Cua E, Molina JM.

Clin Microbiol Infect. 2016 Sep;22(9):757-767. doi: 10.1016/j.cmi.2016.08.029. Epub 2016 Sep 8. Review.

42.

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.

Boyd A, Piroth L, Maylin S, Maynard-Muet M, Lebossé F, Bouix C, Lascoux-Combe C, Mahjoub N, Girard PM, Delaugerre C, Carrat F, Lacombe K, Miailhes P.

J Viral Hepat. 2016 Dec;23(12):1017-1026. doi: 10.1111/jvh.12581. Epub 2016 Aug 3.

PMID:
27486094
43.

High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.

de Truchis P, Lê MP, Daou M, Madougou B, Nouhou Y, Moussa Saley S, Sani A, Adehossi E, Rouveix E, Saidou M, Peytavin G, Delaugerre C.

J Antimicrob Chemother. 2016 Nov;71(11):3222-3227. Epub 2016 Jul 20.

PMID:
27439522
44.

Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.

Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F.

J Hepatol. 2016 Oct;65(4):683-691. doi: 10.1016/j.jhep.2016.05.014. Epub 2016 May 19.

PMID:
27210429
45.

P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART.

Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Lévy Y, Lelièvre JD.

PLoS Pathog. 2016 Apr 15;12(4):e1005571. doi: 10.1371/journal.ppat.1005571. eCollection 2016 Apr.

46.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

47.

Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.

Gazaignes S, Resche-Rigon M, Gatey C, Yang C, Denis B, Fonsart J, Desseaux K, Guionie M, Rozenbaum W, Delaugerre C, Molina JM.

Antivir Ther. 2016;21(4):329-36. doi: 10.3851/IMP3010. Epub 2015 Nov 13.

PMID:
26566057
48.

Comparison of the bioMérieux NucliSENS EasyQ HIV-1 v2.0-HIV-1 RNA quantification assay versus Abbott RealTime HIV-1 and Roche Cobas TaqMan HIV-1 v2.0 on current epidemic HIV-1 variants.

Mourez T, Delaugerre C, Vray M, Lemée V, Simon F, Plantier JC.

J Clin Virol. 2015 Oct;71:76-81. doi: 10.1016/j.jcv.2015.08.007. Epub 2015 Aug 18.

PMID:
26318912
49.

Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.

Boyd A, Maylin S, Moh R, Mahjoub N, Gabillard D, Eholié SP, Danel C, Anglaret X, Zoulim F, Girard PM, Delaugerre C, Lacombefor K; ANRS 12240 VarBVA study.

J Gastroenterol Hepatol. 2016 Mar;31(3):634-44. doi: 10.1111/jgh.13156.

PMID:
26313291
50.

Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification.

Boyd A, Maylin S, Moh R, Gabillard D, Menan H, Mahjoub N, Danel C, Anglaret X, Eholié SP, Girard PM, Zoulim F, Delaugerre C, Lacombe K; ANRS 12240 VarBVA study.

Diagn Microbiol Infect Dis. 2015 Nov;83(3):248-51. doi: 10.1016/j.diagmicrobio.2015.07.009. Epub 2015 Jul 18.

PMID:
26283522

Supplemental Content

Loading ...
Support Center